Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Inflammatory Bowel Diseases

  Free Subscription


15.11.2021

1 Aliment Pharmacol Ther
1 Am J Gastroenterol
1 BMC Gastroenterol
2 Clin Gastroenterol Hepatol
5 Dig Dis Sci
1 Eur J Gastroenterol Hepatol
2 Gastroenterology
4 Inflamm Bowel Dis
1 J Clin Gastroenterol
6 J Crohns Colitis
1 J Immunol
1 PLoS One
1 Scand J Gastroenterol
1 Z Gastroenterol


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. RADHAKRISHNAN ST, Alexander JL, Mullish BH, Gallagher KI, et al
    Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Nov 9. doi: 10.1111/apt.16656.
    PubMed         Abstract available


    Am J Gastroenterol

  2. NGUYEN NH, Martinez I, Atreja A, Sitapati AM, et al
    Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review.
    Am J Gastroenterol. 2021 Nov 9. pii: 00000434-990000000-00141.
    PubMed         Abstract available


    BMC Gastroenterol

  3. LI D, Liang Y, Lu J, Tan Y, et al
    An alternative splicing signature in human Crohn's disease.
    BMC Gastroenterol. 2021;21:420.
    PubMed         Abstract available


    Clin Gastroenterol Hepatol

  4. DEBNATH P, Rathi P
    Treat to Target in Patients with Ileocolonic Crohn's Disease: Endoscopic Remission or Histologic Healing?
    Clin Gastroenterol Hepatol. 2021;19:2452.
    PubMed        

  5. COHEN-MEKELBURG S, Yu X, Costa D, Hofer TP, et al
    Variation in Provider Connectedness Associates With Outcomes of Inflammatory Bowel Diseases in an Analysis of Data From a National Health System.
    Clin Gastroenterol Hepatol. 2021;19:2302-2311.
    PubMed         Abstract available


    Dig Dis Sci

  6. ZHANG J, Li Y, Diao Y, Da B, et al
    Long-Term Outcome of Endoscopic Balloon Dilation for Duodenal Crohn's Disease-Associated Strictures.
    Dig Dis Sci. 2021;66:3570-3577.
    PubMed         Abstract available

  7. YARUR AJ, Deepak P, Vande Casteele N, Battat R, et al
    Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases.
    Dig Dis Sci. 2021;66:3563-3569.
    PubMed         Abstract available

  8. BORREN NZ, Paulides E, Frinack JL, Olson RN, et al
    Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study.
    Dig Dis Sci. 2021;66:3548-3554.
    PubMed         Abstract available

  9. DOU D, Ji Y, Zheng J, Li J, et al
    A New Role for Conivaptan in Ulcerative Colitis in Mice: Inhibiting Differentiation of CD4(+)T Cells into Th1 Cells.
    Dig Dis Sci. 2021 Nov 9. pii: 10.1007/s10620-021-07300.
    PubMed         Abstract available

  10. LUO Y, Cheng Q, Fang Y, Yu J, et al
    Infliximab Therapy in Very Early Onset Crohn's Disease: Real-World Experience in China.
    Dig Dis Sci. 2021;66:3555-3562.
    PubMed         Abstract available


    Eur J Gastroenterol Hepatol

  11. YAO J, Gao R, Luo M, Li D, et al
    Long noncoding RNA KIF9-AS1 promotes cell apoptosis by targeting the microRNA-148a-3p/suppressor of cytokine signaling axis in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2021 Nov 8. pii: 00042737-900000000-97127.
    PubMed         Abstract available


    Gastroenterology

  12. SHAH SC, Itzkowitz SH
    Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management.
    Gastroenterology. 2021 Oct 29. pii: S0016-5085(21)03707.
    PubMed        

  13. BEN-HORIN S, Novack L, Mao R, Guo J, et al
    Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials.
    Gastroenterology. 2021 Oct 29. pii: S0016-5085(21)03709.
    PubMed         Abstract available


    Inflamm Bowel Dis

  14. DALAL RS, Allegretti JR
    Fecal Microbiota Transplantation for Chronic Pouchitis: Promising Novel Therapeutic or Lost Cause?
    Inflamm Bowel Dis. 2021;27:1873-1875.
    PubMed        

  15. JAGT JZ, Struys EA, Ayada I, Bakkali A, et al
    Fecal Amino Acid Analysis in Newly Diagnosed Pediatric Inflammatory Bowel Disease: A Multicenter Case-Control Study.
    Inflamm Bowel Dis. 2021 Nov 10. pii: 6425057. doi: 10.1093.
    PubMed         Abstract available

  16. LUTZ MK, Matthews LA, Tuan WJ, Caldera F, et al
    Did You Get My Message? Trends and Predictors of Inflammatory Bowel Disease Patient-to-Provider Electronic Messaging.
    Inflamm Bowel Dis. 2021 Nov 10. pii: 6425060. doi: 10.1093.
    PubMed        

  17. JENA A, Singh AK, Siddharda BV, Panda P, et al
    Mesalamine-Induced Perimyocarditis: Rare Adverse Event in a Patient With Acute Severe Ulcerative Colitis.
    Inflamm Bowel Dis. 2021 Nov 9. pii: 6425058. doi: 10.1093.
    PubMed        


    J Clin Gastroenterol

  18. BUFFONE E, Gupta S, Al Ibrahim B, Marshall JK, et al
    Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel Disease.
    J Clin Gastroenterol. 2021 Nov 10. pii: 00004836-900000000-97351.
    PubMed         Abstract available


    J Crohns Colitis

  19. SOOP M, Hancock L, Davies J
    Anti-TNF Therapy Before Intestinal Surgery for Crohn's Disease and the Risks of Postoperative Complications.
    J Crohns Colitis. 2021;15:1777.
    PubMed        

  20. MEKORI-DOMACHEVSKY E, Ben-Horin S
    Holistic approach to IBD patients.
    J Crohns Colitis. 2021;15:1782.
    PubMed        

  21. AGRAWAL M, Zhang X, Brenner EJ, Ungaro RC, et al
    The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.
    J Crohns Colitis. 2021;15:1877-1884.
    PubMed         Abstract available

  22. ADAMINA M, Fiorino G
    At the Crossroads of Caution and Intervention: Anti-TNF Therapy Prior to Elective CD Surgery.
    J Crohns Colitis. 2021;15:1778-1779.
    PubMed        

  23. CHARPY F, Altwegg R, Debourdeau A
    Disseminated tuberculosis in a patient treated with tofacitinib for ulcerative colitis.
    J Crohns Colitis. 2021 Nov 9. pii: 6424411. doi: 10.1093.
    PubMed        

  24. VAN ERP LW, Neijenhuis MK, Heida W, Derwig J, et al
    Improving care for recently diagnosed inflammatory bowel disease patients: Lessons learned from a patient-centred, mixed-method study.
    J Crohns Colitis. 2021 Nov 10. pii: 6425110. doi: 10.1093.
    PubMed         Abstract available


    J Immunol

  25. ALI H, Dong SXM, Gajanayaka N, Cassol E, et al
    Selective Induction of Cell Death in Human M1 Macrophages by Smac Mimetics Is Mediated by cIAP-2 and RIPK-1/3 through the Activation of mTORC.
    J Immunol. 2021;207:2359-2373.
    PubMed         Abstract available


    PLoS One

  26. MIYAZAKI C, Katsumasa N, Huang KC, Liu YF, et al
    Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan.
    PLoS One. 2021;16:e0254807.
    PubMed         Abstract available


    Scand J Gastroenterol

  27. TSUJII Y, Nishida T, Osugi N, Fujii Y, et al
    Classification and clinical features of adverse drug reactions in patients with ulcerative colitis treated with 5-aminosalicylate acid: a single-center, observational study.
    Scand J Gastroenterol. 2021 Nov 9:1-7. doi: 10.1080/00365521.2021.1998601.
    PubMed         Abstract available


    Z Gastroenterol

  28. TEICH N, Ludewig C, Schmelz R, Bastlein EC, et al
    [Effects of SARS-CoV-2 Infection on Symptoms and Therapy of Inflammatory Bowel Disease].
    Z Gastroenterol. 2021;59:1189-1196.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: